Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.
about
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationSafety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysisPharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.Lenvatinib and Palbociclib.Lenvatinib: first global approval.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Targeting FGFR in Squamous Cell Carcinoma of the Lung.Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.Contrast-enhanced computerized tomography combined with a targeted nanoparticle contrast agent for screening for early-phase non-small cell lung cancer.Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancerA Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
P2860
Q28079309-B46DDABE-695C-42A9-BE74-72E4D506DF4AQ33433315-CB9A936D-4A3C-4059-9D68-59FD70BEAFCCQ34468729-A4214BED-1C06-4BD3-9943-69AB0AF530F7Q36109982-AAC0BA2C-2022-477F-B769-67DB88DAB338Q38385844-C34D9AA7-A566-41CD-B42B-B65936CACA02Q38525073-E9F17123-CF7C-4FC1-B0C7-C0F45BDC7829Q38690050-D5679038-6CB9-4CEA-B3A7-89C32B3BD0A4Q38702994-FB23C375-884F-4699-B0F7-7BE8D8588BB8Q39011379-CF0B1008-A6E1-438C-92C3-55EA5648ACD5Q39226762-710E43C6-01E6-4F63-864F-9F874DC49343Q46573222-22AE83C6-00EF-4F73-92C7-D3C6BB984109Q47104384-59189371-38C7-4C5D-B93C-66D8DEEA748EQ53520555-2A0F0EFA-AA93-4217-96BD-7F2BDA1A1513Q58572423-7BE026D3-8F25-4915-B16E-97EF60541CB1Q58584938-0116C874-74DD-45EE-9FEA-2421E9B08B67
P2860
Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase 1 study of lenvatinib co ...... th non-small-cell lung cancer.
@ast
Phase 1 study of lenvatinib co ...... th non-small-cell lung cancer.
@en
type
label
Phase 1 study of lenvatinib co ...... th non-small-cell lung cancer.
@ast
Phase 1 study of lenvatinib co ...... th non-small-cell lung cancer.
@en
prefLabel
Phase 1 study of lenvatinib co ...... th non-small-cell lung cancer.
@ast
Phase 1 study of lenvatinib co ...... th non-small-cell lung cancer.
@en
P2093
P2860
P356
P1476
Phase 1 study of lenvatinib co ...... th non-small-cell lung cancer.
@en
P2093
H Murakami
H Nokihara
N Yamamoto
T Takahashi
P2860
P2888
P304
P356
10.1038/BJC.2013.374
P407
P577
2013-07-16T00:00:00Z
P5875
P6179
1047208773